{"entity":{"id":"nct03850795","kind":"trial","name":"HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","aka":[],"tldr":"A phase 3 trial of Deutenzalutamide run by Hinova Pharmaceuticals USA, Inc., terminated.","summary":"HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a phase 3 interventional study registered as NCT03850795 by Hinova Pharmaceuticals USA, Inc., with 104 participants enrolled, started 2021-03-15. Conditions recorded: Prostate Cancer Metastatic and Castration-resistant Prostate Cancer. Interventions recorded: HC-1119 and Enzalutamide.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03850795","url":"https://clinicaltrials.gov/study/NCT03850795"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["deutenzalutamide"],"companies":["hinova-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03850795","phase":"3","setting":"PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","sponsor":"Hinova Pharmaceuticals USA, Inc.","enrolled":104,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03850795/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"drug":[{"id":"deutenzalutamide","kind":"drug","name":"Deutenzalutamide","route":"/drugs/deutenzalutamide/"}],"company":[{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/"}]}}